go-v.orgdoi

Personalized medicine in colorectal cancer: the evidence so far

Avinash Gupta, Wasir Saka, Rachel S. Kerr · Clinical Investigation · 2012

  • DOI 10.4155/cli.12.99
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2012

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2012

Abstract

Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of cancer-related death. Current treatment continues to mostly be determined by stratifying patients into fairly broad groups, according to prognosis based on clinicopathological and histopathological staging. Conventional chemotherapy remains the mainstay of systemic treatment, with no established means of predicting response to treatment. However, greater understanding of the molecular biology underlying colorectal cancer, and the manner in which this influences prognosis and response to systemic therapy is increasingly well understood.

In the future, key genetic changes in an individual patient’s cancer could potentially be used to more accurately predict the risk of relapse following surgery and the likely response to systemic therapy.

Open the resolved locator · 10.4155/cli.12.99

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 23:53 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.12.99
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.